{"id":"W4385751197","doi":"10.1158/1078-0432.ccr-23-1137","title":"Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Medicine; Olaparib; Immunotherapy; Response Evaluation Criteria in Solid Tumors; Immune system; Internal medicine; Oncology; Tumor microenvironment; Toxicity; Immunology; Phases of clinical research; Nivolumab; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001105463,0.0008444389,0.001112971,0.0001988402,0.0001661039,0.0006339707,0.0004671249,0.0005326632,0.001486424],"category_scores_gemma":[0.000667097,0.0002681756,0.0005276345,0.0002183665,0.0005055727,0.0004246293,0.0001882794,0.001261918,0.0002789284],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006051957,"about_ca_system_score_gemma":0.0005523596,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004214491,"about_ca_topic_score_gemma":0.001210375,"domain_scores_codex":[0.9997351,0.0001432708,0.00001586872,0.00003625568,0.00002682786,0.00004274217],"domain_scores_gemma":[0.9995564,0.000086213,0.0001289183,0.0000326662,0.00001608343,0.0001797035],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8357794,0.01161785,0.0113123,0.0007241069,0.001541589,0.0002904362,0.0001367178,0.001992876,0.0349219,0.0001888706,0.002459494,0.09903438],"study_design_scores_gemma":[0.6355096,0.317762,0.03234283,0.00005650807,0.001079903,0.0007077296,0.00006692209,0.002106261,0.007041107,0.0002962661,0.002998397,0.00003242888],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963751,0.001949564,0.0001286597,0.0001780839,0.0000275561,0.0002132965,0.0003852015,0.0000204851,0.0007220129],"genre_scores_gemma":[0.9965887,0.00099611,0.0003841548,0.0002443747,0.00006321057,0.0002746929,0.0007210013,0.000006089801,0.0007217611],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001486424,"threshold_uncertainty_score":0.005846262,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3288032443135986,"score_gpt":0.5626271940113787,"score_spread":0.2338239496977801,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}